Pharmaceutical Executive October 24, 2025
Mike Hollan, Chris O'Dell

Chris O’Dell, SVP of market solutions at Turquoise Health, discusses why it’s important to a shine a light on this aspect of the healthcare ecosystem.

Pharmaceutical Executive: What impact will DTC programs have on prescription drug prices?
Chris O’Dell: I’m optimistic that they will have an impact in the long term. In the near term, however, what was announced has limited impact. At the end of the day, complexity is the enemy here.

The fact that no one knows what a drug is going to cost them before they get it is clearly a problem in the US. Shining a lot on that complexity and showing that list prices on drugs are way too high is something that everyone...

Today's Sponsors

Venturous
ZeOmega

Today's Sponsor

Venturous

 
Topics: Biotechnology, Interview / Q&A, Patient / Consumer, Pharma, Pharma / Biotech, Trends
283: A candid conversation: Physicians on the front lines of GLP‑1 care
BigHat, Revvity Collaborate with Eli Lilly, Immunai Signs Agreement with Bristol Myers Squibb, SandboxAQ Launches New AI Model
Q&A: New PQA Resource Highlights 40 Projects Targeting Social Determinants of Health
NVIDIA and Lilly Announce Co-Innovation AI Lab to Accelerate Drug Discovery
Data Visualization is Broken in Biotech: Q&A with Sunitha Venkat

Share Article